Hospital
Pelham Medical Center
Pelham Medical Center was paid $13.82M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoPELHAM MEDICAL CENTER
GREER, SC 29651
GREER, SC 29651
33aNPI1982800397assigned 06/22/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.82M
24GClaims342,573
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#23 of 115
Median peer was paid$2.47M
This provider vs. median5.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MEINKE, KENNETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,356 | $1.77M | |
| 2019 | 41,999 | $1.82M | |
| 2020 | 35,652 | $1.47M | |
| 2021 | 48,228 | $1.85M | |
| 2022 | 61,996 | $2.51M | |
| 2023 | 62,885 | $2.57M | |
| 2024incomplete | 53,457 | $1.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 20,508 | 17,614 | $2.22M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 30,966 | 27,884 | $1.76M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12% | 5,269 | 4,874 | $1.70M |
| J7030 | Infusion, normal saline solution , 1000 cc | 12% | 9,701 | 7,931 | $1.63M |
| 81001 | 6.3% | 16,059 | 14,452 | $872K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.2% | 6,200 | 5,696 | $853K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 3,415 | 3,068 | $553K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 3.5% | 2,322 | 2,107 | $479K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.9% | 4,764 | 3,756 | $398K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.0% | 2,113 | 1,946 | $276K |
| 87081 | 1.7% | 1,445 | 1,366 | $233K | |
| 81025 | 1.5% | 9,915 | 8,973 | $206K |
144 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 5,008 | $190K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 3,364 | $178K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,733 | $166K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1.0% | 1,121 | $141K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1.0% | 98 | $138K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,532 | $131K |
| 73610 | <1% | 738 | $123K | |
| 87075 | <1% | 656 | $119K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,558 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,146 | $110K |
| 73630 | <1% | 927 | $101K | |
| 99284 | Emergency room visit (serious) | <1% | 12,250 | $84K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 529 | $80K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 105 | $59K |
| 73562 | <1% | 499 | $52K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 498 | $50K |
| 81003 | <1% | 1,344 | $46K | |
| 72100 | <1% | 821 | $44K | |
| 73030 | <1% | 337 | $42K | |
| 93971 | <1% | 300 | $39K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 66 | $38K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,135 | $36K |
| 73110 | <1% | 196 | $33K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 633 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,121 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,629 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,374 | $30K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 970 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,053 | $24K |
| 99285 | Emergency room visit (most serious) | <1% | 4,631 | $24K |
| 73130 | <1% | 170 | $23K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 727 | $22K |
| 84484 | <1% | 6,741 | $21K | |
| 84702 | <1% | 1,128 | $20K | |
| 81015 | <1% | 383 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 41 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,397 | $15K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 175 | $14K |
| 87077 | <1% | 1,051 | $14K | |
| 87807 | <1% | 312 | $14K | |
| 76830 | Ultrasound, transvaginal | <1% | 164 | $11K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 176 | $9K |
| 83690 | <1% | 10,313 | $9K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,232 | $9K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,456 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,182 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,540 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 57 | $5K |
| 74018 | <1% | 81 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 29 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 2,400 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,275 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,572 | $4K |
| 87040 | <1% | 982 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,388 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 29 | $4K |
| 87210 | <1% | 511 | $3K | |
| 85027 | <1% | 2,654 | $3K | |
| 73502 | <1% | 45 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 36 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,420 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,163 | $2K |
| 83880 | <1% | 2,426 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 105 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,557 | $2K |
| J3490 | Unclassified drugs | <1% | 5,042 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 321 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,457 | $2K |
| 86850 | <1% | 183 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 526 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,033 | $2K |
| 85379 | <1% | 1,032 | $2K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $2K |
| 83735 | <1% | 4,700 | $1K | |
| 76536 | <1% | 12 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,637 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 779 | $1K |
| 83605 | <1% | 1,977 | $1K | |
| 85610 | <1% | 2,310 | $904.31 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 918 | $842.90 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,589 | $802.86 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,393 | $622.54 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 510 | $610.29 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 118 | $602.50 |
| 86140 | <1% | 1,164 | $503.03 | |
| 86900 | <1% | 1,002 | $497.07 | |
| 97161 | <1% | 635 | $475.05 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 254 | $445.76 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,987 | $403.13 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,293 | $224.49 |
| 85730 | <1% | 1,978 | $215.47 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,965 | $209.33 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,527 | $155.31 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 57 | $143.05 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,396 | $121.11 |
| 85652 | <1% | 98 | $117.43 | |
| 84439 | <1% | 39 | $113.92 | |
| 80061 | Lipid panel | <1% | 70 | $96.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,191 | $92.49 |
| 82607 | <1% | 15 | $89.30 | |
| 87186 | <1% | 1,103 | $72.73 | |
| 96376 | <1% | 470 | $65.72 | |
| 76801 | <1% | 89 | $61.84 | |
| 82077 | <1% | 590 | $60.66 | |
| 86901 | <1% | 1,002 | $41.37 | |
| 82550 | <1% | 141 | $40.96 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 454 | $27.99 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 573 | $5.96 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,304 | $1.01 |
| A9270 | Non-covered item or service | <1% | 919 | $0.13 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 166 | $0.00 |
| 85007 | 0% | 42 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 198 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 68 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 23 | $0.00 |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 81 | $0.00 |
| 90715 | 0% | 16 | $0.00 | |
| 82272 | 0% | 15 | $0.00 | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | 0% | 28 | $0.00 |
| 84100 | 0% | 74 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 37 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,222 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 931 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 160 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 153 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 408 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 518 | $0.00 |
| 87140 | 0% | 471 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,336 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 87 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 58 | $0.00 |
| 82803 | 0% | 43 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 40 | $0.00 |
| 64483 | 0% | 44 | $0.00 | |
| 97162 | 0% | 117 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 71 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 14 | $0.00 |
| 97165 | 0% | 129 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 63 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEINKE, KENNETH (CFO)
Parent organizationSPARTANBURG REGIONAL HEALTH SERVICES DISTRICT, INC
| Provider | Location | Paid |
|---|---|---|
| Spartanburg Medical Center | Spartanburg, SC | $187.76M |
| Spartanburg Medical Center | Spartanburg, SC | $11.52M |
| Spartanburg Medical Center | Drayton, SC | $8.86M |
| Spartanburg Medical Center | Spartanburg, SC | $4.17M |
| Spartanburg Medical Center | Spartanburg, SC | $3.72M |
| Spartanburg Medical Center | Spartanburg, SC | $1.94M |
| Spartanburg Medical Center | Boiling Springs, SC | $1.92M |
| Spartanburg Medical Center | Spartanburg, SC | $1.39M |
| Spartanburg Medical Center | Spartanburg, SC | $990K |
| Spartanburg Medical Center | Greenville, SC | $943K |
| Spartanburg Medical Center | Spartanburg, SC | $911K |
| Spartanburg Medical Center | Gaffney, SC | $785K |
| Spartanburg Medical Center | Spartanburg, SC | $726K |
| Spartanburg Medical Center | Spartanburg, SC | $680K |
| Spartanburg Medical Center | Inman, SC | $669K |
| Spartanburg Medical Center | Pacolet, SC | $462K |
| Spartanburg Medical Center | Landrum, SC | $446K |
| Spartanburg Medical Center | Spartanburg, SC | $413K |
| Spartanburg Medical Center | Spartanburg, SC | $325K |
| Spartanburg Medical Center | Duncan, SC | $281K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.